Apollon Formularies (AQSE:APOL) Total Assets : £3.96 Mil (As of Jun. 2023)

View and export this data going back to . Start your Free Trial

What is Apollon Formularies Total Assets?

Apollon Formularies's Total Assets for the quarter that ended in Jun. 2023 was £3.96 Mil.

During the past 12 months, Apollon Formularies's average Total Assets Growth Rate was 42.50% per year. During the past 3 years, the average Total Assets Growth Rate was 1.60% per year. During the past 5 years, the average Total Assets Growth Rate was -7.00% per year. During the past 10 years, the average Total Assets Growth Rate was 15.30% per year.

During the past 11 years, Apollon Formularies's highest 3-Year average Total Assets Growth Rate was 604.20%. The lowest was -78.60%. And the median was 0.50%.

Total Assets is connected with ROA %. Apollon Formularies's annualized ROA % for the quarter that ended in Jun. 2023 was -40.13%. Total Assets is also linked to Revenue through Asset Turnover. Apollon Formularies's Asset Turnover for the quarter that ended in Jun. 2023 was 0.01.

Apollon Formularies Total Assets Historical Data

The historical data trend for Apollon Formularies's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies Total Assets Chart

Apollon Formularies Annual Data

Trend

Jun10

Jun11

Dec12

Dec13

Dec14

Dec17

Dec18

Dec19

Dec20

Dec21

Total Assets

Get a 7-Day Free Trial

2.89

2.75

1.28

2.40

3.05

Apollon Formularies Semi-Annual Data
	Jun11	Jun12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Jun23
Total Assets	Get a 7-Day Free Trial											2.40	3.87	3.05	3.66	3.96

Apollon Formularies Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Apollon Formularies's Total Assets for the fiscal year that ended in Dec. 2021 is calculated as

Total Assets	=	Total Equity (A: Dec. 2021 )	+	Total Liabilities (A: Dec. 2021 )
	=	2.963	+	0.083
	=	3.05

Apollon Formularies's Total Assets for the quarter that ended in Jun. 2023 is calculated as

Total Assets	=	Total Equity (Q: Jun. 2023 )	+	Total Liabilities (Q: Jun. 2023 )
	=	2.114	+	1.842
	=	3.96

Apollon Formularies (AQSE:APOL) Total Assets Explanation

Total Assets is connected with ROA %.

Apollon Formularies's annualized ROA % for the quarter that ended in Jun. 2023 is

ROA %	=	Net Income (Q: Jun. 2023 )	/	( (Total Assets (Q: Jun. 2022 )	+	Total Assets (Q: Jun. 2023 ))	/ count )
	=	-1.528	/	( (3.658	+	3.957)	/ 2 )
	=	-1.528	/	3.8075
	=	-40.13 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Apollon Formularies's Asset Turnover for the quarter that ended in Jun. 2023 is

	Asset Turnover
=	Revenue (Q: Jun. 2023 )	/	( (Total Assets (Q: Jun. 2022 )	+	Total Assets (Q: Jun. 2023 ))	/ count )
=	0.048	/	( (3.658	+	3.957)	/ 2 )
=	0.048	/	3.8075
=	0.01

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Apollon Formularies Total Assets Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Apollon Formularies (AQSE:APOL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS

Website

https://www.apollon.org.uk

Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.